AbbVie acquires Syndesi Therapeutics, strengthening neuroscience portfolio
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
A total of 17 labs will be operational across the country by this month
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Serina has over 17 years of experience in the biopharmaceutical industry
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
110 BDS graduates admitted in week one of the launch
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Subscribe To Our Newsletter & Stay Updated